| 615583-16-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• CAS: 615583-16-9
• 化学式: C₃₂H₅₅N₅O₅
• 分子量: 589.819
• InChiKey: UHKHBPCBMDQXKI-QIIGEBQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.51
• 重原子数：
  42.0
• 可旋转键数：
  11.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  153.86
• 氢给体数：
  5.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  在 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 生成 (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyridine-3-carbonylamino)acetyl]amino]-3,3-dimethyl-butanoyl]-N-[(1S)-1-[2-(cyclopropylamino)-2-oxo-acetyl]butyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxamide
  参考文献：
  名称：

  Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics

  摘要：

  Reversible tetrapeptide-based compounds have been shown to effectively inhibit the hepatitis C virus NS3 center dot 4A protease. Inhibition of viral replicon RNA production in Huh-7 cells has also been demonstrated. We show herein that the inclusion of hydrogen bond donors on the P4 capping group of tetrapeptide-based inhibitors result in increased binding potency to the NS3 center dot 4A protease. The capping groups also impart significant effects on the pharmacokinetic profile of these inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.090
• 作为产物：
  描述：

  在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics

  摘要：

  Reversible tetrapeptide-based compounds have been shown to effectively inhibit the hepatitis C virus NS3 center dot 4A protease. Inhibition of viral replicon RNA production in Huh-7 cells has also been demonstrated. We show herein that the inclusion of hydrogen bond donors on the P4 capping group of tetrapeptide-based inhibitors result in increased binding potency to the NS3 center dot 4A protease. The capping groups also impart significant effects on the pharmacokinetic profile of these inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.090